Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$207.9K-27.47%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Geoffrey Stuart Dow
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Beta
- 2.40
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -20.80
Financials
Revenue
$207.9K-27.5%Net Income
$-2.26MEBITDA
$-2.29MFree Cash Flow
$-2.23MEPS (diluted)
$-0.90Shares Outstanding (diluted)
2.65M+10862.7%Operating Expenses
$2.33MCash & Debt
$1.02MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.01M | $-7.37M | $-11.73 |
| 2024 | $607.6K | $-7.95M | $-74.20 |
| 2023 | $253.6K | $-3.77M | $-3.80 |
| 2022 | $223.2K | $-6.18M | $-4.28 |
| 2021 | $1.16M | $-4.25M | $-2.96 |
| 2020 | $2.18M | $-3.03M | $-2.08 |
Valuation
SXTPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Positive
…ents, patient population, regulatory pathway, and post-marketing requirements WASHINGTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it intends to conclude enrollment in its randomized clinical study of tafenoquine in patients hospitalized with severe babesiosis at 30 subjects.
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis ( NCT06207370 ) to be disclosed on October 6, 2026. Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring leading babesiosis experts Dr. Peter Krause and Dr. Edouard Vannier.
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today its financial results for the second quarter of 2026, ended June 30, 2026. Financial Highlights for the Quarter Ended June 30, 2026: Net product revenues increased approximately 106% to approximately $208 thousand …
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.61 per share
Typical surprise -22.4% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.90 vs $-0.73miss
- Fri, May 15$-1.28 vs $-0.76miss
- Thu, Mar 26$-1.69 vs $-2.28beat
- Thu, Nov 13$-2.64 vs $-1.84miss
- Tue, Aug 12$-5.00 vs $-4.96miss
- Thu, May 15$-6.24 vs $-5.24miss
Estimates and results for SXTP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SXTP officers and directors.
- Bought
- $351k
- Sold
- —
24 trades
0 trades
- Dow Geoffrey Sbought
- Dow Geoffrey Sbought
- Dow Geoffrey Sbought
- Dow Geoffrey Sbought
- Xu Cherylbought
- Xu Cherylbought
- Xu Cherylbought
- Xu Cherylbought
57 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SXTP.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.